Bone repair assessment of critical size defects in rats treated with mineralized bovine bone (Bio-Oss®) and photobiomodulation therapy: a histomorphometric and immunohistochemical study.

Abstract

This study aimed to investigate the effects of administering photobiomodulation therapy (PBM) with bovine bone matrix on critical size defects in rats. Seventy-two adult male rats (albinus, Wistar), 90days old, were used. Defect of 5mm in diameter was made in their calvaria. The animals were divided into 4 groups: C-blood clot, B-Bio-Oss®, L-PBM, B+L-Bio-Oss®+PBM. Each group has been subdivided into 07, 30, and 60days of observation. For PBM, a low GaAlAs energy of 660nm was irradiated, total energy density of 45J/cm2 . PBM was conducted in a trans-surgical form once only. For immunohistochemistry, a semi-quantitative analysis was made of expression of osteoprotegerin (OPG), nuclear kappa B-factor ligand receptor activator (RANKL), and tartrate-resistant acid phosphatase (TRAP). All histomorphometric data were statistically analyzed by ANOVA and Tukey test, significance level of 5%. The groups that showed the highest proportion of neoformation were L (0.39% ± 0.13) and C (0.37% ± 0.97), but groups B and B+L had larger defect size (C-1.75mm2± 0.40, B-3.02mm2± 0.63, L-2.45mm2± 0.53, B+L-3.23mm2± 1.01). In immunohistochemistry, groups B and B+L had higher immunostaining scores for OPG and RANKL at 60days, and TRAP immunostaining increased in all groups at 30days, but group L was the only one to present specimens with score 0. Although, at 60days, groups L and C presented the highest proportion of bone neoformation, at 30days group B+L had more than twice as much bone neoformation as group B, the choice of treatment application should depend on the aim of the treatment.